Previous observational epidemiological studies have shown inconsistent results on the relationship between hypnotics use and risk of cancer. To determine the association between hypnotics use and risk of cancer, we conducted a meta-analysis of available literature. Methods: We searched databases PubMed, EMBASE, and the bibliographies of relevant articles to locate additional publications in February 2016. Three evaluators independently reviewed and selected eligible studies based on pre-determined selection criteria. Results: A total of six observational epidemiological studies including three case-control studies and three cohort studies, which involved 1,830,434 participants (202,629 hypnotics users and 1,627,805 non-users), were included in the final analyses. In a random-effects meta-analysis, compared with non-use of hypnotics, the odds ratio for overall hypnotics use was 1.29 for various cancers (95% confidence interval, 1.08-1.53). Subgroup meta-analyses by various factors such as study design, type of case-control study, study region, and methodological quality of study revealed consistent findings. Conclusion: Our findings from a meta-analysis of low-biased epidemiological studies suggested evidence linking the use of hypnotics to an increased risk of cancers. The results should be cautiously interpreted because of considerable heterogeneity with a Higgins I 2 value.
INTRODUCTION
Insomnia has detrimental effects on the quality of life in a large subset of the affected population. 1) Hypnotics are used for treating insomnia symptoms, and the intake of hypnotics is estimated to range between 3% and 12% in general, with a two-fold increase in the intake of hypnotics among the elderly. 2) In addition to other hypnotics, benzodiazepines are prescribed in patients with sleep disorder, anxiety, or panic disorder.
Previous in vitro and animal studies have reported controversial findings on the correlation between benzodiazepine use and the risk of cancer. One animal study reported that benzodiazepines increased the risk of thyroid cancer. 3) Conversely, in vitro laboratory studies indicated that benzodiazepines might have antitumor effects on colorectal and breast adenocarcinoma cells. 4) Epidemiological studies indicated controversial findings on the relationship between hypnotics use and the risk of cancer. For example, a population based case-control study showed no link between benzodiazepine use and the incidence of breast cancer; 5) in contrast, a large cohort study conducted in 62,186 subjects who underwent benzodiazepine treatment in Taiwan suggested that benzodiazepine use could be associated with an increased risk of brain tumor. 6) To date, there are no published quantitative meta-analyses on this
issue. In the current study, we examined the associations between hypnotics use and the risk of cancer by conducting a meta-analysis of observational epidemiological studies including case-control studies and cohort studies.
METHODS

Literature Search
We searched PubMed and EMBASE using common keywords related to hypnotics use and the risk of or mortality from cancer in February 2016. The search was restricted to publication dates between June 1972 and October 2015. The keywords were as follows: for exposure factors, "hypnotics, " "sleep medication, " "sleeping pill, " "benzodiazepine, " "zolpidem, " and "zopiclone"; and for outcome factors, "cancer, "
"tumor, " "carcinoma, " and "neoplasm". We also searched the bibliographies of relevant articles. We did not restrict the search by publication language. Institutional Review Board approval for the study was not required because the current meta-analysis used data that was already published.
Selection Criteria
Observational epidemiological studies that met all of the following criteria were included: (1) case-control study or cohort study; (2) investigated the associations between "hypnotics" and "cancer"; and (3) reported outcome measures with adjusted odds ratios (ORs) or relative risks (RRs) and 95% confidence intervals (CIs). If data were duplicated or shared in more than one study, we included the first published study or the comprehensive study in the analysis. Unpublished studies and abstracts that were only presented in academic conferences or not published in peer-reviewed journals were not included. We made an attempt to contact the authors in case of insufficient data.
Selection of Relevant Studies
Three of the authors (KDH, KYH, and KHB) independently evaluated the eligibility of all studies retrieved from the databases based on the above selection criteria. If disagreements between evaluators occurred, they were resolved by consensus through discussion.
Assessment of Methodological Quality
The methodological quality of included studies was based on the Newcastle-Ottawa Scale (NOS) for assessing the quality of case-control studies and cohort studies in meta-analyses. 7) The NOS has a star system for scores ranging from 0 to 9, with three subscales including se-597 Identified studies from the databases using keywords and bibliographies of relevant articles: PubMed (n=374), EMBASE (n=219), and bibliographies (n=4) lection of studies, comparability, and exposure. Since the criteria for the high-or low-quality of a study is not well established, we considered a study with a higher score than the mean of each study type as a high-quality study.
Main and Subgroup Analyses
In the main analysis, we investigated the associations between the use of hypnotics (highest use versus never used) and the overall risk of all cancers by using adjusted data. We also performed subgroup analyses by type of study design (case-control or cohort study), type of cancer, cancer risk, sex, study region (Europe and Asia), duration of hypnotics use, types of hypnotics, cumulative yearly dose, type of case-control study (population-based or hospital-based), and methodological quality of study (high versus low). We also investigated the association between long-term hypnotics use (hypnotics use ≥1 year) and the risk of cancers. We defined short-term hypnotics use as ever used for duration of less than 6 months.
Statistical Analyses
To calculate OR or RR with its 95% CI, we used the adjusted ORs or RRs and 95% CIs in each study reporting the association between hypnotics use (highest use versus never used) and the risk of cancer. We examined the heterogeneity in the results across studies using the Hig-
, which measures the percentage of total variation across studies. 8) The I 2 was calculated as follows:
where Q is Cochran's heterogeneity statistic; and df is the degrees of freedom. Negative values of I 2 were set at zero; the I 2 value ranges between 0% (no heterogeneity) and 100% (maximal heterogeneity). An I 2 value >50% was considered to indicate substantial heterogeneity. 8) We used a random-effects model meta-analysis based on the DerSimonian and Laird method because individual trials were conducted in different populations. 9) In the final analysis, we evaluated the publi- 
RESULTS
Identification of Relevant Studies
Figure 1 presents a flow diagram for identification of relevant studies.
We extracted a total of 597 articles by searching two databases and searching relevant bibliographies manually. We excluded 206 articles that were duplicated and additional 363 articles that did not fulfil the selection criteria. As a result, we reviewed the full texts of the remaining 28 articles. Among these, 22 articles were excluded because of the following reasons: not relevant to our analysis (n=3), psychotropic 
*Each study can be awarded a maximum of one star for each numbered item within the selection and exposure categories, while a maximum of two stars can be given for the comparability category. 
*Each study can be awarded a maximum of one star for each numbered item within the selection and exposure categories, while a maximum of two stars can be given for the comparability category.
medication use other than hypnotics (n=6), investigating mortality from cancer (n=6), opioid use with hypnotics (n=1), using data from pre-existing cancer (n=5); and using an acute biomarker as indication of exposure (n=1). Finally, the remaining six studies including three cohort studies [10] [11] [12] and three case-control studies [13] [14] [15] were included in the meta-analysis.
Characteristics of Studies Included in the Final Analysis
We identified a total of six observational studies [10] [11] [12] [13] [14] [15] including 1,830,434 participants (202,629 hypnotics users and 1,627,805 non-users). The participants' mean age was 56.9 years (range, 20 to 102 years). Table 1 shows the general characteristics of the included studies. Three studies were conducted in Europe 10, 13, 15) and the other three in Tai- wan. 11, 12, 14) The follow-up period for incident overall cancer ranged between 4 and 12 years, with a median follow-up of 8.3 years. All studies indicated the relationship involving the risk of malignant carcinoma, except one study, 12) which investigated the association only for benign brain tumor. In our meta-analysis, studies were conducted for the following types of hypnotics; zolpidem (n=4), [11] [12] [13] [14] zopiclone (n=3), 10, 13, 14) and benzodiazepines (n=2).
13,14)
Methodological Quality of Studies
We assessed the methodological quality of studies included in the final analysis based on the NOS scores. For all studies, the NOS scores ranged from 6 to 8; for case-control studies, the average score was for 7.3; and for cohort studies, the average score was 6.7. The high-quality studies (score of 8 in case-control studies and 7 in cohort studies) included two case-control studies 13, 14) and two cohort studies (Tables 2,   3 ).
11,12)
Hypnotics Use and the Risk of All Types of Cancer
Hypnotics use was significantly associated with an increased risk of cancer in the random-effects meta-analysis of all six studies (pooled OR/RR, 1.29; 95% CI, 1.08-1.53) (Figure 2 ). On stratification by study design, both case-control and cohort studies showed a positive correlation between hypnotics use and the risk of cancer. Figure 3) ; whereas, heterogeneity was not observed in the zopiclone-and benzodiazepine-user groups (I 2 =37.3% for zopiclone use and 0.0% for benzodiazepine use).
Hypnotics Use and the Risk of Cancer by Type
Hypnotics use showed the strongest association with the risk of esophagus carcinoma ( 
Assessment of Publication Bias
No substantial publication bias was found in the selected studies (Begg's funnel plot was symmetric; and Egger's test, P=0.60).
DISCUSSION
In the current meta-analysis of six observational epidemiological stud- A 15-year prospective cohort study of HCV patients showed that the cumulative risk for HCC increased from 6.4% for low-levels of HCV RNA to 14.7% for high-levels of HCV RNA (P<0.001).
17)
Human immunodeficiency virus (HIV) is a possible factor that links benzodiazepine use to an increased risk of carcinoma. In 1,682 participants without HIV infection at baseline, 18) benzodiazepine use was significantly related with an elevated rate of HIV seroconversion in the 80-month study period (RR, 1.50; 95% CI, 1.01-2.24). Subjects with HIV infection are more susceptible to human papilloma virus (HPV) infection. 19) Additionally, HIV could alter the usual immune response Our meta-analysis has several limitations. First, we only included observational epidemiological studies because there have been few published randomized controlled trials on this topic. Case-control studies are usually more sensitive to recall bias and selection bias than cohort studies, which might result in spurious associations. Also, cohort studies have a lower level of evidence than randomized controlled trials. Another limitation is that a small fraction of the included studies adjusted tobacco smoking and alcohol drinking as confounding factor(s), which are both established factors for the risk of carcinoma;
five studies adjusted tobacco smoking as a confounding factor, and four studies adjusted alcohol drinking as a confounding factor. Thus, we were unable to exclude the confounding efficacy of important factors such as smoking or alcohol drinking on the association between Figure 3 . The association between use of hypnotics and risk of cancer in a randomeffects meta-analysis of observational studies by type of hypnotics (n=6).
